Developing an extensive range of synthetic T cell-priming vaccine and immunotherapy candidates for infectious diseases and immunotherapy indications using core proprietary technologies designed to elicit broad and long-lasting cellular immune responses.
We work on addressing some of the world’s most impactful health threats with a growing pipeline of candidates. Gylden’s T cell-priming vaccine and immunotherapy candidates combine core proprietary technologies. First indications pursued protect against infectious diseases: (1) including core candidates for Betacoronavirus, Dengue Fever, and Universal Influenza (including Pandemic Influenza); as well as (2) intra-cellular bacterial infectious diseases.
Our Vision:
To positively impact global human health though the development of innovative T cell-priming product candidates for some of the world’s most immediate health threats.
Latest press releases
Emergex Announces Company Name Change to “Gylden Pharma Limited” Reflecting Company’s Commitment to Advanced Core Technologies and Expanded Product Pipeline
Emergex T Cell-Priming Vaccine Candidate for Betacoronaviruses selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials
Emergex Receives Patent Protection for First-in-Class Influenza A Vaccines with Potential to Provide Long-Term T Cell Immunity